Complete androgen insensitivity pathophysiology, diagnosis, and managementIMPERATO-MCGINLEY, J; CANOVATCHEL, W. J.Trends in endocrinology and metabolism. 1992, Vol 3, Num 3, pp 75-81, issn 1043-2760Article

Role of orlistat in the treatment of obese patients with type 2 diabetes : A 1-year randomized double-blind studyHOLLANDER, P. A; ELBEIN, S. C; LUCAS, C. P et al.Diabetes care. 1998, Vol 21, Num 8, pp 1288-1294, issn 0149-5992Article

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialLAVALLE-GONZALEZ, F. J; JANUSZEWICZ, A; DAVIDSON, J et al.Diabetologia (Berlin). 2013, Vol 56, Num 12, pp 2582-2592, issn 0012-186X, 11 p.Article

A novel mutation in the CAG triplet region of exon 1 of androgen receptor gene causes complete androgen insensitivity syndrome in a large kindredZHU, Y.-S; CAI, L.-Q; CORDERO, J. J et al.The Journal of clinical endocrinology and metabolism. 1999, Vol 84, Num 5, pp 1590-1594, issn 0021-972XArticle

Luteinizing hormone pulsatility in subjects with 5α-reductase deficiency and decreased dihydrotestosterone productionCANOVATCHEL, W. J; VOLQUEZ, D; HUANG, S et al.The Journal of clinical endocrinology and metabolism. 1994, Vol 78, Num 4, pp 916-921, issn 0021-972XArticle